Literature DB >> 20823029

Relapsing acute disseminated encephalomyelitis in children: further evaluation of the diagnosis.

Nihal Olgac Dundar1, Banu Anlar, Alev Guven, Ayse Serdaroglu, Coskun Yarar.   

Abstract

We examined our cases of relapsing acute disseminated encephalomyelitis (n = 13) in which diagnosis was made before the publication of the International Pediatric Multiple Sclerosis Study Group criteria in 2007, with the aim of reevaluating the primary diagnosis, examining any features indicative of other disorders, and determining the final diagnosis. Mean duration of follow-up was 9.4 (range, 2-20) years. Most (n = 11) were multiphasic, and 2 were recurrent cases. The final diagnosis changed in only 2 patients, both in the multiphasic group: one multiple sclerosis, and one other possible central nervous system vasculitis. All others are still being followed up as relapsing acute disseminated encephalomyelitis and had no further attacks. Six patients in this category did not have encephalopathy at first episode, which suggested the requirement for encephalopathy might be restrictive for certain cases. These results suggest the diagnosis of relapsing acute disseminated encephalomyelitis can be made correctly in most cases by clinical and imaging features.

Entities:  

Mesh:

Year:  2010        PMID: 20823029     DOI: 10.1177/0883073810369260

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  3 in total

1.  Treatment of acute disseminated encephalomyelitis.

Authors:  Daniela Pohl; Silvia Tenembaum
Journal:  Curr Treat Options Neurol       Date:  2012-06       Impact factor: 3.972

Review 2.  Acuted disseminated encephalomyelitis.

Authors:  Joy B Parrish; E Ann Yeh
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

3.  Acquired demyelinating disorders of central nervous system: A pediatric cohort.

Authors:  Sheffali Gulati; Biswaroop Chakrabarty; Atin Kumar; Puneet Jain; Harsh Patel; Lokesh Saini
Journal:  Ann Indian Acad Neurol       Date:  2015-09       Impact factor: 1.383

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.